← brief for 2026-08-26 · Slowing decline

The MUSCLE-GLP1-CKD study: design and rationale of a prospective real-world cohort evaluating muscle health after subcutaneous semaglutide initiation in chronic kidney disease and type 2 diabetes

Paper No results yet Peer reviewed

Key takeaways

This paper describes the plan for a study, not its findings. Researchers will follow people who have both chronic kidney disease and type 2 diabetes after they start semaglutide, a weekly injection also sold as Ozempic, and track what happens to their muscle. The worry is that these drugs cause weight loss that includes muscle, which matters because muscle loss is dangerous in kidney disease. There are no results yet.

Who did this work

Manuel Macía-Heras (Hospital Universitario Nuestra Señora de Candelaria) · Domingo J. Hernández-Marrero (Universidad de La Laguna) · Carlos E. Martínez-Alberto (Hospital Universitario Nuestra Señora de Candelaria) · Orlando Siverio-Morales (Universidad de La Laguna) · Javier Donate‐Correa (Universidad de La Laguna)

Source

Paper · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-08-20
https://doi.org/10.1186/s12882-026-05304-2